Context Therapeutics (NASDAQ:CNTX) Rating Increased to Hold at Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities analysts have also recently commented on CNTX. Lifesci Capital raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. Finally, JonesTrading began coverage on Context Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Price Performance

CNTX opened at $2.88 on Friday. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.62. The firm has a market capitalization of $264.71 million, a P/E ratio of -12.00 and a beta of 1.96. The company’s 50-day moving average is $2.35 and its 200 day moving average is $1.56.

Institutional Trading of Context Therapeutics

Several hedge funds have recently added to or reduced their stakes in CNTX. Blue Owl Capital Holdings LP boosted its stake in Context Therapeutics by 0.3% in the fourth quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Context Therapeutics by 4.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Context Therapeutics in the 4th quarter worth approximately $3,824,000. Marshall Wace LLP lifted its stake in Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.